Navigation Links
Pharmacopeia Announces Management Team Changes
Date:2/28/2008

990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS031291, a product candidate from its chemokine receptor CCR1 program, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, PS178990 and PS031291, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Schering-Plough and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with resp
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
2. Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. West Pharmaceutical Services Announces Quarterly Dividend
6. Beijing 2008 Olympic Games Vegetable Supplier Considering Kiwa as a Supplier of Bio-Fertilizers & Kiwa Announces CEO Interview with WallSt.net
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
9. DARA BioSciences, Inc. Announces Appointment of New Director to Board
10. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
11. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015  Prima Biomed Ltd. (NASDAQ: PBMD ... to become a leader in the development of immunotherapeutic ... the final CVac data from the Phase II CAN-003 ... for a clinically meaningful improvement in Overall Survival ("OS") ... In the group of second remission patients ...
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... Germany (PRWEB) May 21, 2015 ... that its manufacturing facility in Worms, Germany has ... an independent subsidiary of the International Pharmaceutical Excipient ... Grace facilities that produce its SYLOID® FP brand ... received GMP certification, following the Curtis Bay, Maryland ...
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... 10 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... on endocrine therapy and oncology, today announced the opening ... with cetrorelix pamoate for the treatment of benign prostatic ... more than 20 million men in the U.S. alone. ...
... ATLANTA, Georgia, June 10 , ... Elsevier / MC Strategies, a pioneer in ... to announce that five,Clinical e-Learning courses were named as winners ... International,Academy of the Visual Arts (IAVA). With thousands of entries ...
... , Three-of-Four Patients Surveyed Experience Daily Pain From ... the European League Against Rheumatism Annual Congress of ... Results from the Rheumatoid Arthritis: Insights, Strategies ... rheumatoid arthritis (RA) patients throughout Europe and Canada ...
Cached Biology Technology:AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 4AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 5Elsevier / MC Strategies Online Courses Named in the 15th Annual Communicator Awards 2Elsevier / MC Strategies Online Courses Named in the 15th Annual Communicator Awards 3Elsevier / MC Strategies Online Courses Named in the 15th Annual Communicator Awards 4New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 2New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 3New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 4New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 5New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 6
(Date:5/22/2015)... , May 22, 2015 According ... by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, ... (Government and Utilities, Consumer and Home) - Global Forecast ... grow from $2.77 Billion in 2015 to $6.19 Billion ... Browse 79 market data Tables and   43 ...
(Date:5/21/2015)... -- The Sync Project™ , a global collaboration ... announced a collaborative partnership with Berklee,s Institute for ... collaboration on original research, joint course development and an ... The Sync Project and BerkleeICE are exploring the launch ... 2015-2016 academic year.  The course will ...
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... CHICAGO , Sept. 16, 2013  AUTOTESTCON –  Marvin ... Systems ), a trusted provider of innovative test solutions ... company,s involvement in AUTOTESTCON 2013 . The 49th ... Chicago, Illinois for ATE leaders ...
... A new understanding of the essential role of gut microbes ... with some of the more significant health problems facing people ... a new analysis. Problems ranging from autoimmune disease to ... to immune dysfunction that begins with a "failure to communicate" ...
... He heads the Institute for Diabetes and Obesity (IDO) ... director of the Helmholtz Diabetes Center (HDC). The Alexander ... Diseases at the Technische Universitt Mnchen (TUM). His research ... of fat and sugar metabolism, with the objective of ...
Cached Biology News:Marvin Test Solutions Featured at AUTOTESTCON 2013 with Leading Armament Experts and Test Systems 2Marvin Test Solutions Featured at AUTOTESTCON 2013 with Leading Armament Experts and Test Systems 3Gut microbes closely linked to proper immune function, other health issues 2Gut microbes closely linked to proper immune function, other health issues 3